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Abstract: Erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) are known to have
neuroprotective actions. Based on previous reports showing the synergistic effects of EPO+G-CSF
combination therapy in experimental models, we investigated the safety of EPO+G-CSF combination
therapy in patients with chronic stroke. In a pilot study, 3 patients were treated with EPO and G-CSF
for 5 consecutive days, with follow-up on day 30. In an exploratory double-blind study, 6 patients
were allocated to treatment with either EPO+G-CSF or placebo. Treatment was applied once a day
for 5 days per month over 3 months. Participants were followed up for 6 months. To substantiate
safety, vital signs, adverse events, and hematological values were measured on days 0, 5, and 30
in each cycle and on day 180. Functional outcomes were determined on day 0 and 180. In the
laboratory measurements, EPO+G-CSF combination therapy significantly elevated erythropoietin,
CD34+ hematopoietic stem cells, white blood cells, and neutrophils on day 5 of each cycle. There
were no observations of serious adverse events. In the functional outcomes, the grip power of the
dominant hand was increased in the EPO+G-CSF treatment group. In conclusion, this exploratory
study suggests a novel strategy of EPO+G-CSF combination therapy for stroke patients.
Keywords: erythropoietin; granulocyte-colony stimulating factor; combination therapy;
stroke; neuroprotection
1. Introduction
Brain injury from ischemic or hemorrhagic stroke results in tissue destruction in the involved
brain regions and eventually loss of motor function. Although there have been a variety of efforts to
recover motor deficits through training-based interventions, conventional rehabilitation has yielded
limited improvements in stroke patients. Therefore, pharmacological treatment using multiple drugs
such as erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) has been introduced
in clinical trials for stroke patients [1–7].
Hematopoietic growth factors such as EPO and G-CSF have particularly been utilized to increase
circulating blood cells, including red blood cells, white blood cells, and platelets, by stimulating bone
marrow production. EPO is commonly known for regulating red blood cell production in patients
with anemia [8,9], while G-CSF is generally known for acting on CD34+ hematopoietic stem cells to
stimulate neutrophil progenitor proliferation and differentiation in patients with neutropenia, as well
as mobilizing transplanted bone marrow stem cells in patients with hematological malignancies such
as multiple myeloma [10,11].
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In addition to the peripheral effects, these hematopoietic factors also stimulate CD34+
hematopoietic stem cell migration from the bone marrow into the brain region through peripheral
blood circulation [12–14]. EPO acts through beneficial mechanisms to exert anti-apoptotic, antioxidant,
anti-inflammatory, neural stem cell-facilitating, neurotrophic, and neuroprotective effects [2,15,16].
G-CSF has therapeutic potential by mobilizing blood stem cells in humans, leading to neuroprotective
effects and acting against immunotoxicity in mammals [3,12,17,18]. Hematopoietic growth factors help
avoid inevitable therapeutic limitations and complications of stem cell transplantation including
infection, malignancy, and ethical issues [19]. De La Peña et al. [20] also suggested that the
co-administration of G-CSF as an adjunctive therapy with umbilical cord blood cell transplantation
could overcome the therapeutic limitations of a single therapy by enhancing neuroprotective
interactions in animal models.
Ehrenreich et al. [1] demonstrated that high-dose intravenous EPO administration can reach the
central nervous system, with levels in the cerebrospinal fluid 100 times that of the placebo control,
as well as decrease infarct volume after 30 days with no clinical safety issues in patients with acute
ischemic stroke. However, Ehrenreich et al. [2] found that the death rate of acute stroke patients is
related to the interaction between thrombolytic drugs and EPO medication, suggesting that patients
treated with thrombolytic drugs should not receive EPO. This result alludes to beneficial outcomes of
EPO treatment in ischemic stroke patients with no clinical history of current thrombolytic therapy.
Shyu et al. [21] suggested that acute stroke patients who complete five days of G-CSF treatment
showed greater improvement of neurological scores, including stroke severity and motor scale, and
metabolic activity in the area surrounding the infarction core. Although there were no changes in
functional outcome, Sprigg et al. [22] found that G-CSF increased CD34+ hematopoietic stem cells
up to 15-fold at the highest dose compared with placebo, and increased total leukocyte counts up
to approximately 4 times compared with pre-treatment, suggesting mobilization of hematopoietic
stem cells from the bone marrow into peripheral circulation. Floel et al. [23] showed that G-CSF
in chronic stroke patients was tolerable and efficacious, with no adverse events and increased
leukocyte counts. England et al. [24] revealed that G-CSF could raise bone marrow-derived stem
cell mobilization by investigating CD34+ hematopoietic stem cells fates in the brain of subacute stroke
patients, accompanied by the direct effect that given hematopoietic growth factors can cross the
blood-brain barrier and act on neurons in the infarct area [17].
Likewise, hematopoietic growth factors are characterized as well-tolerated therapies in patients
with stroke [19,25–28]. Although many studies of promising hematopoietic neuroprotectants have
been undertaken for stroke treatment, most trials have focused on acute or subacute stroke treatment
with a single administration of either EPO or G-CSF. Previous studies tried to demonstrate the safety
and potential beneficial effects of a single pharmacological treatment using either EPO or G-CSF for
chronic multiple sclerosis and stroke [23,27,29]. However, these previous reports indicated that further
studies are required to clearly demonstrate the safety and feasibility of administering neurotrophic
factors for longer time periods or repeated dosing intervals in patients with chronic brain injury.
The present investigation has been inspired by the distinctive and synergistic beneficial
neuroprotective effects of EPO and G-CSF in patients with brain injury. Based on the promising
results, namely that EPO in combination with G-CSF exerted synergistic effects on tissue plasticity and
functional recovery in an experimental stroke model [30], we firstly designed an exploratory study
to prepare and expand a double-blind, placebo-controlled trial of EPO+G-CSF combination therapy
in chronic stroke patients who had lower risks of treatments than patients in the acute or subacute
stage. Hence, we evaluated the safety and synergistic potential of long-term EPO+G-CSF combination
therapy with repeated administration in patients with chronic stroke. The aim of this study was to
determine the primary safety outcomes of vital signs, adverse events, and laboratory measures, and to
substantiate secondary functional outcomes after EPO+G-CSF combination therapy in patients with
chronic stroke.
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2. Results
2.1. Participants
Three participants who received EPO+G-CSF treatment were included in an open-label pilot
study. A total of six participants were included in an exploratory double-blinded study. Two
arms (3 EPO+G-CSF and 3 placebo control) were matched at baseline (Figure 1 and Table 1).
All participants completed three experimental cycles and the 6-month follow-up evaluation in an
exploratory double-blind study.
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Figure 1. Flow of participants through the study. For a pilot study, three patients with chronic stroke
were treated with subcutaneous recombinant human EPO (300 U/kg) and recombinant human G-CSF
(10 µg/kg) once a day for 5 consecutive days with follow up on day 30. Six patients with chronic
stroke were randomly allocated into two groups (3 EPO+G-CSF and 3 placebo) in an exploratory
double-blind study. The EPO+G-CSF arm w s administered as the s e treatment as t e pilot study
per cycle (one month) over a total of 3 cycles. Th pl cebo arm had th same schedule of subcutaneous
saline injections as treatment arm. After completing three treatment cycles, particip nts in the
double-blind study received follow-up for six months from the start of combination therapy in the
same clinic.
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Table 1. Clinical characteristics of patients at time of enrollment in the study.
Characteristics Open-Label Pilot Study Exploratory Double-Blind Study
EPO+G-CSF (n = 3) EPO+G-CSF (n = 3) Placebo (n = 3)
Age (years; range) 30.00 (25.00–32.00) 45.00 (44.00–45.00) 34.00 (31.50–34.50)
Sex (male/female) 3/0 3/0 2/1
Height (cm) 172.00 (166.50–173.50) 169.00 (167.00–172.00) 170.00 (167.50–172.00)
Weight (kg) 50.60 (49.95–64.30) 65.00 (57.50–72.15) 79.80 (71.40–82.15)
Body Mass Index (kg/m2) 19.50 (18.10–22.50) 22.80 (20.60–24.35) 27.60 (25.35–27.75)
Etiology (ischemic/hemorrhagic) 2/1 1/2 2/1
Damaged Region (BG †/F-P ‡/CR §) 2/1/0 2/1/0 2/0/1
Modified Barthel Index 57.00 (57.00–75.00) 93.00 (82.50–94.00) 96.00 (90.50–98.00)
Mini-Mental Status Examination 29.00 (20.50–29.50) 25.00 (24.50–26.50) 30.00 (30.00–30.00)
SBP ¶ (mmHg) 135.00 (135.00–135.50) 134.00 (128.00–139.50) 135.00 (128.00–136.50)
DBP ** (mmHg) 82.00 (79.50–84.50) 82.00 (76.50–82.00) 87.00 (82.50–90.00)
Heart Rate (pulse/min) 80.00 (75.00–85.50) 64.00 (61.50–83.00) 79.00 (74.50–82.50)
Body Temperature (˝) 37.00 (36.85–37.15) 36.50 (36.50–36.65) 36.70 (36.70–36.75)
Adverse Effects (number)
Back Pain 3 1 0
Headache 2 0 1
Vomiting 1 0 0
Values are mean ˘ SE; † BG: basal ganglia; ‡ F-P: fronto-parietal cortex; § CR: corona radiata; ¶ SBP: systolic
blood pressure; ** DBP: diastolic blood pressure.
2.2. Laboratory Measurements
In the pilot study, compared to pre-treatment, EPO+G-CSF combination therapy (n = 3)
showed increases of erythropoietin concentrations (767.00 (interquartile range; 469.00–1032.00)
versus 16.80 (10.74–16.95) mIU/mL), CD34+ hematopoietic stem cells (40.00 (27.00–63.00) versus
2.00 (1.50–4.00) cells/µL), white blood cells (44.36 (40.27–46.16) versus 6.91 (5.48–8.36) cells/µL), and
neutrophils (84.20 (79.60–86.90) versus 65.40 (63.75–65.85) %) on day 5. The peaks of these four
parameters had returned to baseline on day 30 (Figure 2A–D and Table 2).
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Figure 2. Laboratory measurements for t study. (A) Erythrop iet n con e tration; (B) CD34+
cell; (C) white cell co t; and (D) neutrophil on days 0, 5, and 30 of EPO+G-CSF combination therapy.
EPO+G-CSF treatment showed peaks on four parameters on day 5. The hematological patterns returned
to baseline values on day 30. The line was presented as a median value.
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Table 2. Hematological parameters of the EPO and G-CSF combination therapy in stroke patients in a
pilot study.
EPO+G-CSF (n = 3)
Parameter Normal Range Pre-Treatment Day 5 Day 30
Glucose (mg/dL) 70–110 96.00 (90.50–103.50) 86.00 (81.50–89.00) 86.00 (83.00–92.50)
Creatinine (mg/dL) 0.49–1.19 0.89 (0.77–1.06) 0.92 (0.85–1.03) 0.74 (0.70–0.96)
CRP † (mg/L) 0–8 2.85 (1.43–9.76) 3.03 (2.79–4.08) 2.84 (1.42–5.90)
Reti count ‡ (cells/µL) 20.8–109.6 53.80 (50.90–69.95) 76.40 (71.15–88.85) 41.50 (40.95–49.80)
RBC § (cells/µL) 4.5–6.1 ˆ 106 4.69 (4.37–4.87) 4.94 (4.73–5.18) 4.85 (4.74–5.08)
Hemoglobin (g/dL) 13–17 15.00 (14.45–15.15) 14.20 (14.15–14.35) 14.30 (13.80–14.35)
Hematocrit (%) 40–52 43.00 (42.95–43.05) 43.00 (42.45–43.45) 43.50 (43.05–43.60)
WBC ¶ (cells/µL) 4–10.8 ˆ 103 6.91 (5.48–8.36) 44.36 (40.27–46.16) 6.39 (5.14–6.98)
Neutrophil (%) 20–70 65.40 (63.75–65.85) 84.20 (79.60–86.90) 51.80 (46.90–64.40)
Lymphocyte (%) 15–40 26.80 (25.75–27.10) 9.50 (6.95–10.25) 34.20 (24.55–40.70)
Monocyte (%) 2–8 5.90 (5.50–6.35) 4.80 (4.45–5.90) 6.50 (6.25–7.50)
EPO ** (mIU/mL) 3.5–16.2 16.80 (10.74–16.95) 767.00 (469.00–1032.00) 9.24 (7.09–12.32)
CD34+ (cells/µL) - 2.00 (1.50–4.00) 40.00 (27.00–63.00) 1.00 (1.00–2.00)
Values are median (interquartile range); † CRP: C-reactive protein; ‡ Reti count: Reticulocyte count; § RBC: red
blood cell; ¶ WBC: white blood cell; ** EPO: erythropoietin.
In an exploratory double-blind study, compared to placebo treatment (n = 3), EPO+G-CSF
combination therapy (n = 3) significantly elevated erythropoietin concentrations (547.00 (419.50–601.00)
versus 8.89 (7.46–13.35) mIU/mL, p = 0.049) by Mann-Whitney U test, CD34+ hematopoietic stem cells
(50.00 (33.00–61.00) versus 1.00 (1.00–3.00) cells/µL, p = 0.046), white blood cells (32.56 (29.59–45.68)
versus 6.41 (5.93–7.44) cells/µL, p = 0.049), and neutrophils (85.80 (85.40–86.75) versus 59.30
(55.85–60.50)%, p = 0.049) on day 5 (Figure 3A–D and Table 3). EPO+G-CSF treatment also showed a
significant increase in reticulocyte counts and immature red blood cells (92.90 (82.40–95.50) versus 48.80
(44.45–52.75) cells/µL, p = 0.049) on day 5 (Table 3). On the other hand, EPO+G-CSF treatment did
not change red blood cell counts, hematocrit, or hemoglobin values (Table 3). Hematological values
returned to baseline on day 30. These hematological patterns repeated every three cycles and returned
to baseline values in participants who completed 3 cycles of intervention (Figure 3A–D and Table 3).
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Figure 3. Laboratory measures for a total of 3 cycles in an exploratory double-blind study.
(A) Erythropoietin concentration; (B) CD34+ cell; (C) white cell count; and (D) neutrophil on days 0, 5,
and 30 of each cycle, and 6-month by EPO+G-CSF combination therapy or placebo control. EPO+G-CSF
group showed significant peaks on four parameters on day 5 compared with placebo control in each
cycle. The hematological patterns repe ted every three cycles and returned to baseline values in
particip nts who completed 3 cycles of intervention. Values are media * p < 0.05 by Mann-Whitney
U test.
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Table 3. Hematological parameters of the EPO and G-CSF combination therapy in stroke patients in an exploratory double-blind study.
EPO+G-CSF (n = 3)
Parameter Normal Range Day 0 Day 5 Day 30 Day 35 Day 60 Day 65 Day 90 Day 180
Glucose (mg/dL) 70–110 89.00 (82.50–93.50) 108.00 (97.00–113.00) 90.00 (90.00–92.50) 80.00 (77.00–88.00) 90.00 (86.50–135.00) 113.00 (106.00–125.00) 100.00 (96.50–103.50) 107.00 (105.00–122.00) *
Creatinine (mg/dL) 0.49–1.19 1.06 (0.89–1.13) 1.09 (0.94–1.17) 0.95 (0.86–1.08) 1.05 (0.92–1.10) 1.07 (0.96–1.11) 1.23 (0.99–1.24) 0.95 (0.87–1.07) 1.17 (0.97–1.22)
CRP † (mg/L) 0–8 0.40 (0.20–2.00) 8.20 (6.84–13.70) 0.50 (0.25–0.50) 10.70 (6.99–12.40) 0.60 (0.30–0.60) 5.40 (5.33–13.55) * 0.60 (0.30–0.85) 1.40 (0.95–1.49)
Reti count ‡ (cells/µL) 20.8–109.6 61.20 (56.00–65.45) 92.90 (82.40–95.50) * 31.10 (26.95–41.30) 82.00 (74.80–82.15) 20.00 (18.85–26.10) 58.50 (47.35–70.90) 25.20 (24.50–30.60) 81.20 (73.80–86.60)
RBC § (cells/µL) (4.5–6.1) ˆ 106 4.18 (4.11–4.44) 4.20 (4.18–4.35) 4.60 (4.37–4.81) 4.67 (4.61–4.83) 4.64 (4.60–4.66) 4.81 (4.75–5.01) 4.94 (4.91–5.04) 4.32 (4.24–4.58)
Hemoglobin (g/dL) 13–17 12.80 (12.40–13.65) 12.70 (12.60–13.35) 14.20 (13.25–15.05) 14.50 (14.20–15.00) 14.00 (13.70–14.15) 14.70 (14.35–15.40) 14.90 (14.45–15.10) 13.20 (12.90–14.10)
Hematocrit (%) 40–52 38.20 (36.80–41.15) 38.10 (37.95–40.70) 42.70 (40.00–45.25) 42.80 (42.45–45.30) 42.00 (41.85–43.00) 44.20 (44.05–46.75) 46.20 (44.40–46.25) 38.90 (37.95–41.25)
WBC ¶ (cells/µL) (4–10.8) ˆ 103 7.52 (6.15–7.53) 32.56 (29.59–45.68) * 5.39 (4.99–6.71) 41.96 (39.51–48.73) * 5.17 (4.69–5.65) 43.79 (37.16–49.95) * 5.98 (5.73–7.50) 6.55 (5.71–7.44)
Neutrophil (%) 20–70 56.50 (55.70–60.55) 85.80 (85.40–86.75) * 55.00 (44.55–62.85) 86.40 (85.10–87.20) * 51.20 (47.55–52.95) 88.40 (85.30–89.50) * 58.70 (51.85–63.55) 56.20 (53.10–60.95)
Lymphocyte (%) 15–40 31.10 (29.15–33.50) 6.90 (6.80–8.45) * 30.40 (26.50–41.65) 6.80 (6.20–8.60) * 35.50 (33.30–41.15) 7.10 (6.30–9.80) * 25.90 (25.85–35.15) 29.50 (27.50–35.15)
Monocyte (%) 2–8 5.80 (5.05–6.75) 4.90 (3.90–4.95) 6.10 (5.45–6.40) 4.20 (3.45–4.25) 5.70 (4.80–6.25) 2.40 (2.35–3.10) * 4.70 (4.15–7.10) 6.90 (6.05–7.10)
EPO ** (mIU/mL) 3.5–16.2 7.30 (5.65–9.40) 547.00 (419.50–601.00) * 4.28 (3.64–6.89) 421.00 (325.00–570.00) * 5.30 (4.40–7.46) 420.00 (361.00–590.00) * 5.20 (4.10–6.15) * 10.60 (9.65–11.75)
CD34+ (cells/µL) - 1.00 (0.50–2.50) 50.00 (33.00–61.00) * 1.00 (1.00–3.50) 28.00 (18.00–78.50) * 2.00 (1.50–4.00) 56.00 (30.00–73.00) 4.00 (2.50–4.00) 2.00 (2.00–2.50)
Placebo (n = 3)
Parameter Normal Range Day 0 Day 5 Day 30 Day 35 Day 60 Day 65 Day 90 Day 180
Glucose (mg/dL) 70–110 87.00 (84.50–89.50) 100.00 (95.50–122.00) 99.00 (94.00–99.50) 90.00 (85.50–97.00) 95.00 (94.50–106.50) 89.00 (88.50–95.50) 98.00 (95.50–98.00) 90.00 (88.00–94.00)
Creatinine (mg/dL) 0.49–1.19 1.09 (1.02–1.12) 1.04 (0.99–1.12) 1.12 (1.02–1.15) 1.13 (0.98–1.14) 1.13 (1.01–1.22) 1.07 (0.91–1.25) 1.14 (1.02–1.15) 1.02 (1.00–1.08)
CRP † (mg/L) 0–8 0.00 (0.00–0.00) 1.65 (0.83–16.25) 0.50 (0.25–0.94) 0.50 (0.25–1.04) 0.50 (0.25–0.79) 0.50 (0.25–1.24) 2.02 (1.01–2.05) 0.44 (0.22–1.26)
Reti count ‡ (cells/µL) 20.8–109.6 84.10 (71.60–97.05) 48.80 (44.45–52.75) 53.20 (52.15–95.95) 80.00 (54.00–85.10) 89.10 (69.00–107.95) 58.80 (58.00–101.75) 82.70 (58.45–86.45) 74.50 (68.75–82.35)
RBC § (cells/µL) (4.5–6.1) ˆ 106 5.02 (4.55–5.14) 4.89 (4.44–4.96) 5.09 (4.66–5.23) 4.49 (4.39–4.82) 5.08 (4.74–5.26) 4.83 (4.51–5.06) 4.73 (4.59–5.26) 5.10 (4.71–5.45)
Hemoglobin (g/dL) 13–17 14.60 (13.55–15.00) 14.80 (13.35–14.85) 15.40 (14.10–15.45) 13.80 (13.35–14.55) 15.10 (14.25–15.45) 14.60 (13.65–15.35) 14.30 (13.85–16.10) 15.00 (13.95–16.45)
Hematocrit (%) 40–52 44.00 (39.95–44.15) 42.50 (38.85–42.75) 43.70 (40.55–44.90) 38.40 (38.30–41.60) 44.00 (41.40–45.20) 41.80 (39.35–43.85) 40.60 (40.15–45.55) 43.80 (40.95–47.15)
WBC ¶ (cells/µL) (4–10.8) ˆ 103 9.57 (7.63–9.60) 6.41 (5.93–7.44) 9.33 (8.29–10.23) 10.48 (8.11–10.58) 10.06 (8.01–10.45) 7.01 (6.53–8.49) 11.11 (7.66–11.20) 7.32 (6.53–9.22)
Neutrophil (%) 20–70 56.90 (56.45–60.50) 59.30 (55.85–60.50) 66.40 (60.50–71.85) 66.60 (59.50–69.90) 65.70 (60.05–68.90) 65.60 (55.40–73.25) 67.40 (58.80–69.55) 67.40 (56.65–68.10)
Lymphocyte (%) 15–40 30.70 (28.25–31.55) 29.70 (28.60–32.25) 24.70 (20.36–30.30) 23.70 (20.95–27.40) 26.10 (23.30–28.30) 23.80 (22.25–30.90) 24.10 (21.65–29.45) 24.10 (23.00–30.60)
Monocyte (%) 2–8 6.30 (5.55–6.30) 6.60 (5.40–6.80) 4.40 (4.30–4.85) 4.90 (3.95–5.30) 4.60 (4.60–4.70) 5.30 (5.20–6.05) 5.40 (5.35–5.90) 5.30 (4.90–5.55)
EPO ** (mIU/mL) 3.5–16.2 7.93 (7.52–9.42) 8.89 (7.46–13.35) 8.65 (7.36–9.93) 11.10 (10.41–12.55) 6.60 (3.72–10.70) 12.90 (11.15–13.25) 11.80 (11.60–13.80) 11.40 (10.95–12.10)
CD34+ (cells/µL) - 2.00 (2.00–3.00) 1.00 (1.00–3.00) 2.00 (1.50–4.50) 2.00 (1.50–4.00) 1.00 (1.00–4.00) 2.00 (1.50–5.50) 1.00 (1.00–3.50) 2.00 (1.50–4.00)
Values are median (interquartile range); * p < 0.05; † CRP: C-reactive protein; ‡ Reti count: Reticulocyte count; § RBC: red blood cell; ¶ WBC: white blood cell; ** EPO: erythropoietin.
Int. J. Mol. Sci. 2016, 17, 463 7 of 14
2.3. Clinical Outcomes
Mild to severe adverse events were monitored in all participants. A total of 20 side effects were
considered using a checklist (Table 4). In the open-label pilot study, all participants who received
EPO+G-CSF suffered from mild lower back pain, two of three participants suffered from headache,
and one of three participants showed intermittent vomiting during the 5 consecutive days of treatment.
Table 4. Adverse events from EPO+G-CSF administration in all participants.
Adverse Effects (Number)
Open-Label Pilot Study Exploratory Double-Blind Study
EPO+G-CSF (n = 3) EPO+G-CSF (n = 3) Placebo (n = 3)
Shock 0 0 0
Seizure 0 0 0
Dyspnea 0 0 0
High blood pressure 0 0 0
Hemorrhagic accident 0 0 0
Myocardial/cerebral infarction 0 0 0
Jaundice 0 0 0
Allergy 0 0 0
Itching and rash 0 0 0
Stomachache 0 0 0
Dyspepsia 0 0 0
Vomiting 1 0 0
Diarrhea 0 0 0
Headache 2 0 1
Dizziness 0 0 0
Fever 0 0 0
Chill 0 0 0
Insomnia 0 0 0
Fatigue 0 0 0
Skeletal muscle pain 3 1 0
Values are number of subjects.
In an exploratory double-blind study, one of 3 participants who received EPO+G-CSF suffered
from mild lower back pain during the 5 consecutive days of each treatment period (Table 4). However,
there were no observations of serious adverse events such as cardiovascular complications, infections,
or mortality. No significant deviations from the normal range were found in vital signs including
systolic and diastolic blood pressure, pulse rate, and body temperature after EPO+G-CSF combination
therapy or placebo treatment. No participants had evidence of pneumonia or heart problems in chest
X-rays and electrocardiograms up to 6 months after treatment.
In the pre-treatment evaluation of cognitive and functional levels, there were no differences
between the EPO+G-CSF and placebo groups in mini-mental status examination (MMSE) and modified
Barthel index (MBI). This result suggested that initial conditions of groups were well matched. Six
months after treatment, no significant differences had emerged with respect to MMSE and MBI
between groups. Grip and pinch power (tip, lateral, and palmar pinch) and hand dexterity evaluated
by the box-and-block test in the affected hand did not show significant differences between groups
(Table 5). However, the grip power of the dominant hand was significantly increased in the EPO+G-CSF
treatment group compared to placebo control (46.00 (40.00–49.00) versus 39.00 (33.35–39.50) kg, p = 0.049
by Mann-Whitney U test) (Table 5).
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Table 5. Hand function outcomes of the EPO and G-CSF combination therapy in an exploratory double-blind study.
Hand Side Evaluation Contents Normal Range
Day 0 Day 180
EPO+G-CSF (n = 3) Placebo (n = 3) EPO+G-CSF (n = 3) Placebo (n = 3)
Affected Hand
Grip Power (kg) 46.9–48.3 0.00 (0.00–17.00) 1.00 (0.50–23.50) 0.00 (0.00–22.00) 4.00 (2.00–16.50)
Tip Pinch Power (kg) 5.1–6.7 0.00 (0.00–2.25) 0.00 (0.00–2.00) 0.00 (0.00–2.75) 0.00 (0.00–2.00)
Lateral Pinch Power (kg) 7.6–9.5 0.00 (0.00–4.25) 2.50 (1.25–6.75) 0.00 (0.00–5.25) 2.00 (1.00–3.50)
Palmar Pinch Power (kg) 9.3–9.8 0.00 (0.00–3.75) 0.00 (0.00–2.50) 0.00 (0.00–4.50) 0.00 (0.00–2.50)
Box and Block (numbers) 81–83 0.00 (0.00–29.00) 0.00 (0.00–25.00) 0.00 (0.00–37.00) 12.00 (6.00–32.00)
Dominant Hand
Grip Power (kg) 46.9–48.3 42.00 (39.00–47.00) 38.00 (35.00–43.00) 46.00 (44.00–49.00) * 39.00 (33.50–39.50)
Tip Pinch Power (kg) 5.1–6.7 7.50 (6.75–8.00) 4.50 (4.00–5.50) 7.50 (6.50–8.25) 4.50 (4.25–6.75)
Lateral Pinch Power (kg) 7.6–9.5 11.00 (10.00–11.50) 10.00 (8.00–11.00) 9.50 (9.25–9.75) 5.50 (5.25–8.25)
Palmar Pinch Power (kg) 9.3–9.8 10.00 (9.50–10.00) 5.50 (5.00–6.50) 12.00 (10.50–12.00) 5.00 (5.00–7.50)
Box and Block (numbers) 81–83 67.00 (62.00–69.00) 58.00 (55.00–61.00) 79.00 (71.00–80.50) 62.00 (58.00–65.00)
Values are median (interquartile range). * p < 0.05.
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3. Discussion
This study is the first exploratory double-blind study based on the pilot study to evaluate
long-term EPO+G-CSF combination therapy with repetitive administration in patients with chronic
stroke. Although EPO and G-CSF have been commonly used individually as hematopoietic growth
factors in the treatment of anemia and neutropenia, these pharmacological agents have been recently
reported to have neuroprotective and regenerative potential as neurotrophic factors in stroke [27,31,32].
Therefore, we examined a novel approach of administering EPO and G-CSF concurrently, which
has been known to exert synergistic effects in promoting angiogenesis, neurogenesis and functional
recovery in experimental stroke models [30,33]. Although combined administration of EPO and
G-CSF represents a promising therapeutic strategy for stroke patients, most studies have focused on
peripheral efficacy for the treatment of myelodysplastic syndromes [34–37]. Based on these previous
reports showing the therapeutic advantages of an EPO and G-CSF combination [30,33], we evaluated
whether EPO+G-CSF combination therapy safely yielded hematological and functional improvement
in stroke patients.
We found that repetitive and long-term combined use of EPO and G-CSF was well tolerated and
not associated with serious adverse events, supporting the safety of dual administration in stroke
patients. Although serious concerns remain for cardiovascular and hematopoietic events based on
the use of hematopoietic growth factors due to increased production of peripheral blood cells, no
complications leading to thromboembolic accidents or aggravation leading to mortality occurred in
this study [1,2,23,24,38]. Rather, mild adverse events such as musculoskeletal pain and headache were
observed during the five consecutive days of each treatment period.
In the laboratory measurements, we found that EPO+G-CSF treatment significantly elevated
erythropoietin, CD34+ hematopoietic stem cells, white blood cells, and neutrophils in the peripheral
blood in patients with chronic stroke. All participants who received EPO+G-CSF achieved the peak
values on day 5 in each cycle, followed by a hematological trend to return toward baseline within 30
days after drug administration. Despite significant increases of white blood cells and neutrophils, the
EPO+G-CSF group did not show significant complications of vascular events such as thromboembolic
accidents that might worsen primary stroke symptoms, consistent with previous reports [19,23].
While reticulocyte levels increased, red blood cells, hematocrit and hemoglobin did not increase in
accordance with other studies [1,4]. An increase of hematocrit carries the potential risk of high blood
pressure followed by thromboembolic events and further secondary ischemic injury [39]. However,
our study demonstrated that blood pressure did not deviate from the normal range after EPO+G-CSF
combination therapy. The hematological responses during EPO+G-CSF treatment focused on the safety
of combined administration of EPO and G-CSF as neuroprotective agents.
In the functional outcomes of MMSE and MBI, no statistically significant difference was found
between the EPO+G-CSF and placebo groups. It might be possible that chronic stroke participants,
who showed no cognitive impairment and ADL with minimal assist, represent a ceiling effect to the
combination therapy since they already have relatively higher functional level in the initial assessment.
Although no significant differences between groups were seen with respect to functional improvement
on power and dexterity in the affected hand, there was a significant improvement in the grip power of
the dominant hand 6 months after EPO+G-CSF combination therapy.
Previous studies indicate that hematopoietic growth factors encourage functional improvement
in disability, dependence, and cognitive functions in patients with acute stroke or coronary artery
disease [21,38]. Because our participants were in a chronic stage, we might have expected to
observe an improvement of fine motor functions rather than gross motor functions involved in daily
activities [23,24]. The present clinical trial of EPO+G-CSF combination therapy should be interpreted
with caution due to the limited sample size. Small numbers of subjects in this study were not gender
and age matched, resulting in reduced statistical power. The nature of our longitudinal study with
serial intervention per cycle (one month) over a total of 3 cycles and six months follow-up during
a whole procedure, causing inconvenient participation, may represent limitations of our study. As
Int. J. Mol. Sci. 2016, 17, 463 10 of 14
another limitation, we missed D-mannitol as a vehicle of G-CSF in the placebo control. Although
we should have considered two vehicles (saline and D-mannitol), D-mannitol did not affect the
double-blind test because its color and agent form were the same as normal saline, as colorless liquid.
4. Materials and Methods
4.1. Study Design and Ethics
We performed a pilot study followed by an exploratory double-blind study of EPO+G-CSF
combination therapy in patients with chronic stroke. We conducted this trial in accordance with the
Declaration of Helsinki and Good Clinical Practices. The present study was approved by Institutional
Review Board of Severance Hospital, Korea Food and Drug Administration (4-2010-0468), and
registered on an international registry system, ClinicalTrials.gov (NCT02018406).
4.2. Participant Screening and Enrollment
After obtaining signed informed consent, patients were screened using medical history, a physical
assessment, routine blood laboratory tests, and brain magnetic resonance imaging (MRI) findings to
confirm study eligibility.
Inclusion criteria were as follows: (1) over 20 years old; (2) voluntary participants; and (3) at least
3 months after onset of ischemic or hemorrhagic stroke. Exclusion criteria were as follows: (1) under
20 years old; (2) participants who could not voluntarily consent; (3) encephalopathy from brain
tumor and infection; (4) current thrombolytic therapy including warfarin or coumadin medications;
(5) leukopenia, thrombocytopenia, or polycythemia; (6) malignant diseases, malignant hypertension,
myeloproliferative disorder, septic embolism, or hyperkalemia; (7) hepatic or renal dysfunction
with serum creatinine >3 mg/dL; (8) allergic reactions to exogenous EPO or G-CSF; (9) possessing
exclusion criteria for MRI test; (10) pregnant or breast feeding in women; (11) body temperature
over 38 ˝C; (12) blood pressure over 140/90 mmHg at pre-treatment; (13) blood pressure over
160/100 mm Hg during intervention; (14) hemoglobin > 15 g/dL at pre-treatment; (15) hemoglobin >
17 g/dL during intervention; (16) pneumonia detected by chest X-ray; and (17) recurrent history of
aspiration pneumonia.
In an open-label pilot study, participants consented to be treated with EPO+G-CSF for
5 consecutive days, and be followed up on day 30. In an exploratory double-blind study, following
enrollment of eligible participants, randomization was carried out in an institutional clinical pharmacy.
A clinical pharmacist unfamiliar with participants and investigators used a table of random sampling
numbers to randomly allocate participants to either the placebo or EPO+G-CSF arm.
4.3. Drug Administration
Three patients with chronic stroke participated in a pilot study. They were treated with
subcutaneous recombinant human EPO (300 U/kg, CJ HealthCare Corp., Seoul, Korea) in the sodium
chloride solution (10,000 U/mL) and recombinant human G-CSF (10 µg/kg, CJ HealthCare Corp.,
Seoul, Korea) in the D-mannitol solution (250 µg/mL) separately at the same time, once a day for
5 consecutive days, with follow-up on day 30.
Six patients with chronic stroke (3 EPO+G-CSF and 3 placebo) were randomly allocated into two
groups in an exploratory double-blind study. The EPO+G-CSF arm were administered as the same
treatment as the pilot study per cycle (one month) over a total of 3 cycles. The placebo arm had the
same schedule and volume of subcutaneous saline injections as the treatment arm. These doses were
in line with the published safety data [1,23,24].
After completing three treatment cycles, participants were followed up for six months from the
start of combination therapy in the same clinic. To substantiate safety, vital signs, adverse events,
and hematological tests were recorded at each follow-up visit in all patients. To measure functional
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outcomes, MMSE, MBI, grip and pinch power tests and box-and-block tests were performed on days
0 and 180. All patients completed a six-month follow-up (Figure 1).
4.4. Laboratory Measures
Hematological examinations to measure erythropoietin concentration, CD34+ hematopoietic
stem cells, white blood cells including neutrophils, lymphocytes, and monocytes, red blood cells,
reticulocytes, hemoglobin, hematocrit, glucose, creatinine, and C-reactive protein were conducted on
days 0, 5, 30 in each cycle, and 6 months after treatment commenced. Blood samples were obtained
via venous puncture by medical laboratory scientists, and analyzed according to the institutional
standard guidelines as follows. (1) Serum EPO concentration was measured by an enzyme-labeled
chemiluminescent immunometric assay using an immunoassay system (Immulite 2000 XPi, Siemens,
NY, USA); (2) CD34+ cell count was performed using a flow cytometer and software (Navios, Beckman
Coulter, Villepinte, France); (3) Total white blood cells and differentiated subtypes (neutrophils,
lymphocytes, and monocytes), red blood cells, reticulocytes, hemoglobin, hematocrit were measured
using automated blood cell counters (ADVIA 2120i, Siemens, NY, USA; XN-10, XN-20, Sysmex,
Kobe, Japan); (4) Glucose was measured by the hexokinase method using a commercial kits with
an automated chemistry analyzer (Hitachi 7600-200-DDP, Hitachi Ltd., Tokyo, Japan); (5) Creatinine
was measured by the Jaffe method using a commercial kit with an automated chemistry analyzer
(Hitachi 7600-210-DDP, Hitachi Ltd., Tokyo, Japan); (6) C-reactive protein was measured by the
turbidimetric latex agglutination method, using a commercial kit with an automated biochemical
analyzer (Hitachi 7600 P module, Hitachi Ltd., Tokyo, Japan).
4.5. Clinical Outcomes
Vital signs (blood pressure, heart rate, and body temperature) and adverse events were evaluated
on the 5 consecutive treatment days, day 30 in each cycle, and 6 months after treatment commenced.
Vital signs were measured by nurses using an automatic blood pressure monitor (TM-2655, A&D
Co., Ltd., Tokyo, Japan) and an digital thermometer (DT-502EC, A&D Co., Ltd., Tokyo, Japan). Chest
X-rays (KXO-80XM, TOSHIBA, Tokyo, Japan) and electrocardiograms (MAC 5000, GE Marquette
Medical Systems, Milwaukee, WI, USA) were evaluated to screen and exclude pneumonia and heart
failure on days 0 and 180. Functional outcome measures including MMSE, MBI, grip and pinch power,
and the box-and-block test for hand dexterity were evaluated on days 0 and 180. MMSE evaluates
cognitive functions such as registration, attention, calculation, recall, language, ability to follow simple
commands, and orientation. MMSE scores range from 0 to 30, with a lower score indicating cognitive
impairment and the highest score indicating no cognitive impairment [40]. MBI contains 10 items
of activities in daily living (ADL) such as feeding, grooming, dressing, bathing, toilet use, transfer,
mobility, stair climbing, bowel control, and bladder control. MBI scores range from 0 to 100, with a
lower score indicating impediment and a higher score indicating independence [41]. Grip and pinch
power of both hands was measured using a Jamar hand-held dynamometer (PC 5030J1, Preston Co.,
Carson City, NV, USA) and a Jamar hydraulic pinch gauge (PC 5030HPG, Preston Co., Carson City,
NV, USA). The maximum gauge of each participant was recorded [42]. The box-and-block test was
performed using two adjacent boxes over a partition. One of them was filled with 150 cube-shaped
blocks (2.5 cm3). A participant moved blocks from one box to the other. The number of blocks moved
within 60 seconds was counted by occupational therapists [43]. All medical information and clinical
measures for each participant were evaluated by medical laboratory scientists, nurses, radiological
technicians and occupational therapists blinded to the trial.
4.6. Statistical Analysis
All statistical analyses were performed with SPSS Statistics 23 (IBM Corp., Armonk, NY, USA).
Statistical analyses were performed after all participants completed experimental procedures. Median
and interquartile ranges (25th–75th percentiles) were used for the non-normally distributed variables.
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Mann-Whitney U tests were used to compare groups for treatment effects. Statistical significance was
defined as p < 0.05.
5. Conclusions
This study provides a novel strategy of EPO+G-CSF combination therapy for stroke patients.
Based on the safety outcomes of EPO+G-CSF combination therapy in chronic stroke patients, further
clinical trials are required to expand the sample size of chronic stroke patients and inclusion criteria
including acute or subacute stroke patients to test the efficacy of EPO+G-CSF combination therapy.
Therefore, the design of our further study will be considered as a single cycle in large numbers of
stroke patients as a neuroprotective strategy. Ultimately, it will provide a definite therapeutic rationale
by showing the utility of this combination therapy in a large-sample-size study. Taken together, this
exploratory double-blind study after a pilot study provides the first evidence that EPO+G-CSF may
have safe and beneficial therapeutic potential for chronic stroke patients.
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Abbreviations
BG Basal ganglia
CR Corona radiata
CRP C-reactive protein
DBP Diastolic blood pressure
EPO Erythropoietin
F-P Fronto-parietal cortex
G-CSF Granulocyte-colony stimulating factor
MBI Modified Barthel index
MMSE Mini-mental status examination
MRI Magnetic resonance imaging
RBC Red blood cell
Reti count Reticulocyte count
SBP Systolic blood pressure
WBC White blood cell
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